Moufarrij Sara, Gazzo Andrea, Rana Satshil, Selenica Pier, Abu-Rustum Nadeem R, Ellenson Lora H, Liu Ying L, Weigelt Britta, Momeni-Boroujeni Amir
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gynecol Oncol. 2024 Dec;191:1-9. doi: 10.1016/j.ygyno.2024.09.008. Epub 2024 Sep 13.
Endometrial carcinoma (EC) has different molecular subtypes associated with varied prognosis. We sought to characterize the molecular features of ECs with POLE hotspot mutations and concurrent mismatch repair (MMR) deficiency/high microsatellite instability (MSI).
We identified POLE-mutated (POLEmut), MMR-deficient (MMRd)/MSI-high (MSI-H), or combined POLEmut/MMRd ECs subjected to clinical tumor-normal panel sequencing between 2014 and 2023. Clonality of somatic mutations, MSI scoring, tumor mutational burden (TMB), proportion of somatic insertions and deletions (indels), and single base substitution (SBS) mutational signatures were extracted.
We identified 41 ECs harboring POLE exonuclease domain hotspot mutations, 138 MMRd and/or MSI-H ECs, and 14 POLEmut/MMRd ECs. Among the 14 POLEmut/MMRd ECs, 11 (79 %) exhibited clonal POLE hotspot mutations; 4 (29 %) had a dominant POLE-related mutational signature, 4 (29 %) displayed dominant MMRd-related signatures, and 6 (43 %) had mixtures of POLE, aging/clock, MMRd, and POLEmut/MMRd-related SBS mutational signatures. The number of single nucleotide variants was higher in POLEmut/MMR-proficient (MMRp) and in POLEmut/MMRd ECs compared to POLE wild-type (wt)/MMRd EC (both p < 0.001). Small indels were enriched in POLEwt/MMRd ECs (p < 0.001). TMB was highest in POLEmut/MMRd EC compared to POLEmut/MMRp and POLEwt/MMRd ECs (both p < 0.001). Of 14 patients with POLEmut/MMRd EC, 21 % had a recurrence, versus 10 % of those with POLEmut/MMRp EC. Similar findings were noted in 3 POLEmut ECs in patients with Lynch syndrome; akin to somatic POLEmut ECs, these tumors had high TMB.
POLEmut/MMRd ECs may be genetically distinct. Further studies are needed to assess the impact on outcomes and treatment response within this population.
子宫内膜癌(EC)具有不同的分子亚型,其预后各异。我们试图描述具有POLE热点突变并同时存在错配修复(MMR)缺陷/高微卫星不稳定性(MSI)的EC的分子特征。
我们确定了2014年至2023年间接受临床肿瘤-正常样本组测序的POLE突变型(POLEmut)、MMR缺陷型(MMRd)/MSI高(MSI-H)或合并的POLEmut/MMRd EC。提取体细胞突变的克隆性、MSI评分、肿瘤突变负荷(TMB)、体细胞插入和缺失(indel)比例以及单碱基替换(SBS)突变特征。
我们鉴定出41例携带POLE核酸外切酶结构域热点突变的EC、138例MMRd和/或MSI-H EC以及14例POLEmut/MMRd EC。在这14例POLEmut/MMRd EC中,11例(79%)表现出克隆性POLE热点突变;4例(29%)具有主要的POLE相关突变特征,4例(29%)表现出主要的MMRd相关特征,6例(43%)具有POLE、衰老/时钟、MMRd以及POLEmut/MMRd相关的SBS突变特征的混合。与POLE野生型(wt)/MMRd EC相比,POLEmut/MMR熟练型(MMRp)和POLEmut/MMRd EC中的单核苷酸变异数量更高(均p<0.001)。小indel在POLEwt/MMRd EC中富集(p<0.001)。与POLEmut/MMRp和POLEwt/MMRd EC相比,POLEmut/MMRd EC中的TMB最高(均p<0.001)。在14例POLEmut/MMRd EC患者中,21%出现复发,而POLEmut/MMRp EC患者的复发率为10%。在林奇综合征患者的3例POLEmut EC中也观察到类似结果;与体细胞POLEmut EC相似,这些肿瘤具有高TMB。
POLEmut/MMRd EC在基因上可能具有独特性。需要进一步研究来评估对该人群预后和治疗反应的影响。